GLP-1 receptor agonists are effective weight-loss medications, but they may also decrease muscle mass, raising concerns about ...

Accounting for mortality as competing risk, the Afib burden trended numerically in favor of the GLP-1 RA group (HR 0.85, 95% ...

SGLT2 inhibitors and GLP-1 agonists are class 1 medications, but many Medicaid patients have challenges with access.

A new weight loss drug that's being trialled as a daily pill and could rival Ozempic has delivered some astonishing results.

Expanding Medicare coverage for glucagon-like peptide 1 (GLP-1) receptor agonists could significantly reduce obesity-related ...

The rising use of GLP-1 agonists to help manage the obesity epidemic is not only reshaping how consumers taking the ...

Experts express alarm that GLP-1 RAs may trigger or worsen eating disorders. But is there any role they might play in binge ...

Tirzepatide is now approved for the treatment of obstructive sleep apnea, highlighting the drug class' potential in sleep medicine.

Taking the drug made one writer feel so sick she quit and focused on healthy habits instead of her body size. Turns out, 65% ...

Topline data were announced from a phase 3 trial evaluating orforglipron in adults with T2D and inadequate glycemic control with diet and exercise alone.

Weight loss injections boost the glucagon-like peptide-1 (GLP-1) hormone, which is a naturally produced hormone in the ...

A new study from Rutgers University links higher body dissatisfaction, BMI, and maladaptive weight loss behaviors with ...